Registry of Patients Treated With Systemic Mold-Active Triazoles
- Conditions
- Invasive Fungal Infection
- Interventions
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 2015
- Registration Number
- NCT03066011
- Locations
- 🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03065959
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT03056690
- Locations
- 🇺🇸
Site US10025 - Achieve Clinical Research, LLC, Birmingham, Alabama, United States
🇺🇸Site US10045 - TriWest Research Associates, El Cajon, California, United States
🇺🇸Site US10039 - Superior Research LLC, Sacramento, California, United States
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Other: Treatment patterns among AML patientsOther: AML-related healthcare resources
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1027
- Registration Number
- NCT03047083
- Locations
- 🇺🇸
Sermo, Charlotte, North Carolina, United States
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
- Conditions
- Subjects With NSCLC With an EGFR Activating Mutation
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT03042013
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT02997202
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Virginia G Piper Cancer Center, Scottsdale, Arizona, United States
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT02960022
- Locations
- 🇺🇸
Site US10052, Anchorage, Alaska, United States
🇺🇸Site US10011, Tucson, Arizona, United States
🇺🇸Site US10040, Los Angeles, California, United States
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT02927262
- Locations
- 🇺🇸
Site US10017, Gainesville, Florida, United States
🇺🇸Site US10030, Jacksonville, Florida, United States
🇺🇸Site US10012, Chicago, Illinois, United States
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
- Conditions
- Kidney TransplantationPrimary Focal Segmental Glomerulosclerosis (FSGS)
- Interventions
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02921789
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸Stanford School of Medicine, Palo Alto, California, United States
🇺🇸UCSF, San Francisco, California, United States
A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02867306
- Locations
- 🇲🇩
Site MD37301, Chisinau, Moldova, Republic of